2-[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-3a-yl]-2-oxoacetic acid | 1326312-00-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-3a-yl]-2-oxoacetic acid
• CAS: 1326312-00-8
• 化学式: C₃₃H₄₈O₆
• 分子量: 540.741
• InChiKey: QGUDPBTXJSXSMP-AFZJCUFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  97.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-3a-yl]-2-oxoacetic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 生成
  参考文献：
  名称：

  [EN] CARBONYL DERIVATIVES OF BETULIN
  [FR] DÉRIVÉS CARBONYLES DE BÉTULINE

  摘要：

  揭示了一种由以下化学式I或其药学上可接受的盐所表征的化合物，以及包含所述化合物或其药学上可接受的盐的药物组合物，其中R3、L和A如申请中所述。所述化合物对治疗HIV有用。

  公开号：

  WO2013020245A1
• 作为产物：
  描述：

  [(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-5a,5b,8,8,11a-pentamethyl-3a-(2-nitroacetyl)-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl] acetate 在 溶剂黄146 、 sodium nitrite 作用下， 以 二甲基亚砜 为溶剂， 生成 2-[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-3a-yl]-2-oxoacetic acid
  参考文献：
  名称：

  LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF

  摘要：

  本发明涉及鲁班萜三萜衍生物及其药用，具体涉及公式(I)˜(III)的鲁班萜三萜衍生物、含有鲁班萜三萜衍生物或其药用可接受盐的药物组合物和联合制剂，以治疗有效剂量中含有鲁班萜三萜衍生物或其药用可接受盐，特别涉及用于制备治疗HIV-1/AIDS的药物的用途。

  公开号：

  US20150011517A1

文献信息

• [EN] DERIVATIVES OF BETULIN<br/>[FR] DÉRIVÉS DE BÉTULINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011100308A1

  公开（公告）日：2011-08-18

  The present invention relates to a compound characterized by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X, and Y are as described herein. Compounds of the present invention are useful for the treatment of HIV-1.

  本发明涉及一种由化学式I或其药用可接受盐所表征的化合物，其中R1、R2、R3、X和Y如本文所述。本发明的化合物对HIV-1的治疗具有用途。
• [EN] LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉS DE TRITERPÉNOÏDES DE LUPANE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：JIANGXI QINGFENG PHARMACEUTICAL INC

  公开号：WO2013117137A1

  公开（公告）日：2013-08-15

  Disclosed are lupane triterpenoid derivatives and pharmaceutical use thereof, specifically lupane triterpenoid derivatives of formulae (I)~(III), a pharmaceutical composition and a combination preparation comprising said lupane triterpenoid derivatives or a pharmaceutically acceptable salt thereof in a therapeutically-effective dose, particularly the use in preparation of a medicament for the treatment of HIV-1/AIDS.

  本文披露了鲁班三萜衍生物及其药用，具体为公式(I)~(III)的鲁班三萜衍生物，以及包含所述鲁班三萜衍生物或其药用可接受盐的药物组合物和联合制剂，在治疗有效剂量中使用，特别是在制备治疗HIV-1/AIDS的药物中的应用。
• Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms
  作者：Jun Tang、Stacey A. Jones、Jerry L. Jeffrey、Sonia R. Miranda、Cristin M. Galardi、David M. Irlbeck、Kevin W. Brown、Charlene B. McDanal、Brian A. Johns

  DOI：10.1016/j.bmcl.2017.04.042

  日期：2017.6

  A new class of betulin-derived a-keto amides was identified as HIV-1 maturation inhibitors. Through lead optimization, GSK8999 was identified with IC50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. When tested in a panel of 62 HIV-1 isolates covering a diversity of CA-SP1 genotypes including A, AE, B, C, and G using a PBMC based assay, GSK8999 was potent against 57 of 62 isolates demonstrating an improvement over the first generation maturation inhibitor BVM. The data disclosed here also demonstrated that the new alpha-keto amide GSK8999 has a mechanism of action consistent with inhibition of the proteolytic cleavage of CA-SP1. (C) 2017 Elsevier Ltd. All rights reserved.
• DERIVATIVES OF BETULIN
  申请人：Gao Daxin

  公开号：US20120302534A1

  公开（公告）日：2012-11-29

  The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , X, and Y are as described herein. Compounds of the present invention are useful for the treatment of HIV-1.
• US9428542B2
  申请人：——

  公开号：US9428542B2

  公开（公告）日：2016-08-30